A phase I, randomized, double-blind, placebo-controlled study to determine the safety, tolerability, pharmacokinetics, food effect and pharmacodynamics of single and multiple ascending doses of P7435 in healthy, overweight and/or obese subjects
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2016
At a glance
- Drugs P 7435 (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Apr 2013 Planned End Date changed from 1 Jul 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 01 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.